Does measuring pre or post bronchodilator FEV1 influence the level of asthma control in patients with controlled or partially controlled asthma as measured by GINA scale? Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases Year: 2013
Correlation of various parameters with FEV1 in the assessment of asthma severity Source: Eur Respir J 2001; 18: Suppl. 33, 51s Year: 2001
Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Variability and lack of predictive ability of asthma end-points in clinical trials Source: Eur Respir J 2002; 20: 1102-1109 Year: 2002
Normal lung function and absence of bronchodilator response in children with stable, controlled asthma using inhaled corticosteroids Source: Annual Congress 2006 - New features of paediatric asthma Year: 2006
The relationship between symptoms, medication use and PEFR variability with endotoxin concentration in children with asthma Source: Annual Congress 2007 - Epidemiology of paediatric asthma: genes, environment and prognosis Year: 2007
Symptoms, but not PEF, change during an exacerbation in COPD Source: Eur Respir J 2003; 22: Suppl. 45, 238s Year: 2003
Does satisfaction with inhaled asthma treatment correspond with spirometric parameters? Source: Eur Respir J 2006; 28: Suppl. 50, 501s Year: 2006
Oral or inhaled corticosteroids for patients with chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=281 Year: 2006
The derivation of a new index of severity for COPD patients, the DOSE index: MRC d yspnea scale, airflow o bstruction, s moking status and e xacerbations Source: Annual Congress 2007 - Predicting factors of patients undergoing rehabilitation Year: 2007
Salmeterol/fluticasone combination product (SFC) provides better asthma control compared to high dose fluticasone (FP) in symptomatic patients with asthma Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how? Year: 2005
Variability in airway inflammation, symptoms, lung function and reliever use in asthma: anti-inflammatory reliever hypothesis and STIFLE study design Source: ERJ Open Res, 6 (2) 00333-2019; 10.1183/23120541.00333-2019 Year: 2020
Maintenance plus as-needed budesonide/formoterol vs salmeterol/fluticasone in a real-life setting Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how? Year: 2005
Improvement in asthma control by using leukotriene receptor antagonists: results of an experience-based report in Swiss medical practice Source: Annual Congress 2006 - New developments in the treatment and management of asthma Year: 2006
Bronchodilator reversibility (BDR) - should we measure it in adults with symptoms but without obstructed spirometry? Source: Virtual Congress 2021 – Primary care diagnosis and multimorbidities Year: 2021
Asthma symptoms, SABA use, and lung function before and after a moderate or severe exacerbation Source: International Congress 2017 – Many faces of asthma and allergies Year: 2017
Does an acute FEV1 response predict long-term improvements with bronchodilators in patients with COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001
Concordance between oscillometric and spirometric lung function measures in bronchodilator response test for the detection of airway obstruction Source: International Congress 2016 – What's new in paediatric respiratory physiology? Year: 2016
Change in clinical COPD questionnaire (CCQ) symptoms domain score and FEV1 predict treatment failure during hospitalisation due to COPD exacerbations Source: Eur Respir J 2007; 30: Suppl. 51, 525s Year: 2007
Exploring the clinical utility of measuring reversibility in mid expiratory flow and its relationship with FEV1 reversibility in patients with asthma. Source: International Congress 2017 – Biomarker-based asthma control Year: 2017